source
- FDA expands Pluvicto label, allowing most metastatic prostate cancer patients to receive the therapyThe U.S. Food and Drug Administration has approved an expanded label for Novartis’ radiopharmaceutical Pluvicto, permitting its use together with hormone therapy in metastatic prostate cancer. The…
- Medicare to End Extra Payments for FDA Breakthrough Devices Starting FY2028Medicare announced that it will eliminate the special pathways that have let medical devices labeled as breakthrough by the FDA receive supplemental payments without showing a clear clinical advant…